Francois Davodeau

Nantes, 44000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Optimized pipeline for generating highly potent neutralizing Affitins: Application to SARS-CoV-2 spike protein.

Optimized pipeline for generating highly potent neutralizing Affitins: Application to SARS-CoV-2 spike protein.

Journal: International journal of biological macromolecules

Published: May 02, 2025

Development of potent Affitin-based bispecific NK cell engagers for the therapy of MSLN-expressing cancers.

Development of potent Affitin-based bispecific NK cell engagers for the therapy of MSLN-expressing cancers.

Journal: Molecular therapy. Oncology

Published: March 14, 2025

SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for Human.

SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for Human.

Journal: Frontiers in oncology

Published: July 11, 2019

Locoregional Confinement and Major Clinical Benefit of 188Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma.

Locoregional Confinement and Major Clinical Benefit of 188Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma.

Journal: Theranostics

Published: January 30, 2017

Alpha-Radioimmunotherapy: principle and relevance in anti-tumor immunity

Alpha-Radioimmunotherapy: principle and relevance in anti-tumor immunity

Journal: Medecine sciences : M/S

Published: May 04, 2016

Long-Term Toxicity of 213Bi-Labelled BSA in Mice.

Long-Term Toxicity of 213Bi-Labelled BSA in Mice.

Journal: PloS one

Published: December 16, 2015

Production and characterization of monoclonal antibodies specific for canine CD138 (syndecan-1) for nuclear medicine preclinical trials on spontaneous tumours.

Production and characterization of monoclonal antibodies specific for canine CD138 (syndecan-1) for nuclear medicine preclinical trials on spontaneous tumours.

Journal: Veterinary and comparative oncology

Published: November 03, 2015

Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model.

Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model.

Journal: Frontiers in medicine

Published: July 30, 2015

Alpha Particles Induce Autophagy in Multiple Myeloma Cells.

Alpha Particles Induce Autophagy in Multiple Myeloma Cells.

Journal: Frontiers in medicine

Published: July 30, 2015

Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction.

Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction.

Journal: PloS one

Published: February 26, 2015

Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones.

Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones.

Journal: Trends in pharmacological sciences

Published: December 10, 2014

Radioimmunoconjugates for the treatment of cancer.

Radioimmunoconjugates for the treatment of cancer.

Journal: Seminars in oncology

Published: December 03, 2014

Showing 1-12 of 18

Last Updated: 09/26/2026